Search Results - "Ribeiro, Carolina T"

Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome by Signorelli, Flavio, Balbi, Gustavo Guimarães Moreira, Aikawa, Nadia E, Silva, Clovis A, Kupa, Léonard de Vinci Kanda, Medeiros-Ribeiro, Ana C, Yuki, Emily FN, Pasoto, Sandra G, Saad, Carla GS, Borba, Eduardo F, Seguro, Luciana Parente Costa, Pedrosa, Tatiana, Oliveira, Vitor Antonio de Angeli, Costa, Ana Luisa Cerqueira de Sant’Ana, Ribeiro, Carolina T, Santos, Roseli Eliana Beseggio, Andrade, Danieli Castro Oliveira, Bonfá, Eloisa

“…Objective Coronavirus disease 19 (COVID-19) has an increased risk of coagulopathy with high frequency of antiphospholipid antibodies (aPL). Recent reports of…”
Get full text

2019-EULAR/ACR classification criteria domains at diagnosis: predictive factors of long-term damage in systemic lupus erythematosus by Insfrán, Carlos E., Aikawa, Nadia E., Pasoto, Sandra G., Filho, Dilson M. N., Formiga, Francisco F. C., Pitta, Ana C., Borba, Eduardo F., Ribeiro, Carolina T., Silva, Clovis A., Bonfa, Eloisa

“…The objective of this study is to assess the role of the 2019-European League Against Rheumatism/American College of Rheumatology (2019-EULAR/ACR)…”
Get full text

Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial by Medeiros-Ribeiro, Ana C., Aikawa, Nadia E., Saad, Carla G. S., Yuki, Emily F. N., Pedrosa, Tatiana, Fusco, Solange R. G., Rojo, Priscila T., Pereira, Rosa M. R., Shinjo, Samuel K., Andrade, Danieli C. O., Sampaio-Barros, Percival D., Ribeiro, Carolina T., Deveza, Giordano B. H., Martins, Victor A. O., Silva, Clovis A., Lopes, Marta H., Duarte, Alberto J. S., Antonangelo, Leila, Sabino, Ester C., Kallas, Esper G., Pasoto, Sandra G., Bonfa, Eloisa

“…CoronaVac, an inactivated SARS-CoV-2 vaccine, has been approved for emergency use in several countries. However, its immunogenicity in immunocompromised…”
Get full text